Signal Pharmaceuticals, Tanabe Seiyaku deal

The companies agreed to discover enzyme targets to treat inflammatory diseases and osteoporosis. Tanabe will fund the four-year effort through a combination of equity, licensing fees and R&D support totaling $46 million. Tanabe also will pay milestones.

In return, Tanabe is responsible for preclinical and clinical development of drug candidates and receives exclusive marketing rights in Asia. ...